## Final list of IPO additions

**Effective December 20, 2021**

<table>
<thead>
<tr>
<th>Ticker</th>
<th>Company Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACT</td>
<td>Enact Holdings</td>
</tr>
<tr>
<td>AIP</td>
<td>Arteris</td>
</tr>
<tr>
<td>AIRS</td>
<td>Airsculpt Technologies</td>
</tr>
<tr>
<td>AKA</td>
<td>AKA Brands Holding</td>
</tr>
<tr>
<td>ARIS</td>
<td>Aris Water Solutions</td>
</tr>
<tr>
<td>AURA</td>
<td>Aura Biosciences</td>
</tr>
<tr>
<td>AVDX</td>
<td>AvidXchange Holdings</td>
</tr>
<tr>
<td>CDRE</td>
<td>Cadre Holdings</td>
</tr>
<tr>
<td>COCO</td>
<td>The Vita Coco Company</td>
</tr>
<tr>
<td>DICE</td>
<td>Dice Therapeutics</td>
</tr>
<tr>
<td>DTC</td>
<td>Solo Brands</td>
</tr>
<tr>
<td>ENFN</td>
<td>Enfusion</td>
</tr>
<tr>
<td>ESMT</td>
<td>EngageSmart</td>
</tr>
<tr>
<td>FNA</td>
<td>Paragon 28</td>
</tr>
<tr>
<td>FWRG</td>
<td>First Watch Restaurant Group</td>
</tr>
<tr>
<td>HLTH</td>
<td>Cue Health</td>
</tr>
<tr>
<td>HRT</td>
<td>HireRight Holdings</td>
</tr>
<tr>
<td>INKT</td>
<td>Mink Therapeutics</td>
</tr>
<tr>
<td>ISO</td>
<td>Isoplexis</td>
</tr>
<tr>
<td>LTH</td>
<td>Life Time Group Holdings</td>
</tr>
<tr>
<td>LUCD</td>
<td>Lucid Diagnostics</td>
</tr>
<tr>
<td>LVLU</td>
<td>Lulus Fashion Lounge Holdings</td>
</tr>
<tr>
<td>PRCT</td>
<td>Procept Biorobotics</td>
</tr>
<tr>
<td>PTLO</td>
<td>Portillos</td>
</tr>
<tr>
<td>PYXS</td>
<td>Pyxis Oncology</td>
</tr>
<tr>
<td>RELY</td>
<td>Remitly Global</td>
</tr>
<tr>
<td>RENT</td>
<td>Rent the Runway</td>
</tr>
<tr>
<td>SDIG</td>
<td>Stronghold Digital Mining</td>
</tr>
<tr>
<td>SOPA</td>
<td>Society Pass</td>
</tr>
<tr>
<td>SOVO</td>
<td>Sovos Brands</td>
</tr>
<tr>
<td>STER</td>
<td>Sterling Check</td>
</tr>
<tr>
<td>TCBX</td>
<td>Third Coast Bancshares</td>
</tr>
<tr>
<td>THRN</td>
<td>Thorne HealthTech</td>
</tr>
<tr>
<td>THRX</td>
<td>Theseus Pharmaceuticals</td>
</tr>
</tbody>
</table>
Initial public offering additions
Russell 2000® Index

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Company Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRDA</td>
<td>Entrada Therapeutics</td>
</tr>
<tr>
<td>TYRA</td>
<td>Tyra Biosciences</td>
</tr>
<tr>
<td>UDMY</td>
<td>Udemy</td>
</tr>
<tr>
<td>VTYX</td>
<td>Ventyx Biosciences</td>
</tr>
<tr>
<td>WEAV</td>
<td>Weave Communications</td>
</tr>
<tr>
<td>XLO</td>
<td>Xilio Therapeutics</td>
</tr>
</tbody>
</table>
About FTSE Russell

FTSE Russell is a leading global provider of benchmarking, analytics and data solutions for investors, giving them a precise view of the market relevant to their investment process. A comprehensive range of reliable and accurate indexes provides investors worldwide with the tools they require to measure and benchmark markets across asset classes, styles or strategies.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.

FTSE Russell is focused on applying the highest industry standards in index design and governance, employing transparent rules-based methodology informed by independent committees of leading market participants. FTSE Russell fully embraces the IOSCO Principles and its Statement of Compliance has received independent assurance. Index innovation is driven by client needs and customer partnerships, allowing FTSE Russell to continually enhance the breadth, depth and reach of its offering.

FTSE Russell is wholly owned by London Stock Exchange Group.

For more information, visit www.ftserussell.com.